CD8A and neoplasm: After ACTL treatment, the patient’s immune status dramatically reversed: the IFN-γ level surged to 32.4 pg/ml, and the CD4+/CD8+ ratio rose to 6.2, accompanied by significant regression of tumor lesions and eventual achievement of cCR.